Pharmaceutical Market Research Company in Brazil

BioNixus provides primary pharmaceutical market research in Brazil across four practice areas: (1) HCP and KOL research — quantitative physician surveys and qualitative depth interviews with prescribers, formulary decision-makers, and CONITEC assessors across oncology, cardiovascular, diabetes, immunology, and infectious disease; (2) patient and caregiver research — LGPD-compliant patient journey mapping, treatment experience studies, and quality-of-life instrument validation conducted with CEP ethics clearance under Resolution CNS 510/2016; (3) pricing and market access research — willingness-to-pay analysis, CMED price corridor benchmarking, SUS vs. private channel value proposition testing, and CONITEC submission support evidence; and (4) launch and competitive intelligence — launch readiness tracking, share-of-voice analysis, and competitive positioning surveys timed to ANVISA approval milestones.

ANVISA (Agência Nacional de Vigilância Sanitária) restricts promotional communication with healthcare professionals but does not prohibit non-promotional scientific market research. BioNixus designs all Brazilian pharma research materials to comply with the ANVISA promotional code and INTERFARMA self-regulatory guidelines — framing studies as scientific inquiry rather than promotional activity, aligning honoraria with CFM (Conselho Federal de Medicina) guidance, and obtaining medical affairs and legal sign-off on recruitment scripts before fieldwork. For clinical data and patient research, CONEP ethics review via a CEP (Comitê de Ética em Pesquisa) is required under Resolution CNS 510/2016 — BioNixus works with CEP-registered academic hospital partners to sponsor ethics clearance efficiently.

CONITEC (Comissão Nacional de Incorporação de Tecnologias no SUS) evaluates clinical and economic evidence for SUS reimbursement decisions. CONITEC assessments require health technology assessment (HTA) dossiers covering clinical efficacy, comparative effectiveness, cost-utility analysis (cost/QALY or cost/LYG), and budget impact from the SUS perspective. BioNixus supports CONITEC submissions by generating Brazil-specific primary evidence: physician willingness-to-prescribe surveys establishing unmet need, patient burden-of-disease interviews informing QALY calculations, and payer decision-maker research mapping SUS formulary committee priorities. Evidence grounded in Brazilian primary research — rather than extrapolated from European or US studies — strengthens CONITEC submissions and PCDT protocol proposals.

CMED (Câmara de Regulação do Mercado de Medicamentos) regulates maximum pharmaceutical prices in Brazil through the PCFAR (Preço de Fábrica) and PMC (Preço Máximo ao Consumidor) framework. CMED uses a reference basket of 12 countries (including France, Italy, Spain, Portugal, Greece, New Zealand, Canada, Japan, South Korea, Australia, United States, United Kingdom) to set maximum factory prices for new products. BioNixus pharmaceutical pricing research maps the SUS vs. private channel price differential, assesses payer and prescriber price sensitivity, evaluates branded vs. generic substitution triggers, and stress-tests launch price scenarios against CMED ceiling constraints — providing commercial teams with empirical Brazilian market data before CMED price filing.

The five largest therapy areas for pharmaceutical market research in Brazil are: (1) Oncology — Brazil has the highest cancer incidence in Latin America; SUS has expanded INCA-affiliated cancer centre treatment protocols significantly; biosimilar oncology agents and targeted therapies are growing; (2) Diabetes — Brazil has 16 million diagnosed diabetic patients (6th largest globally); GLP-1 agonists and SGLT-2 inhibitors are in rapid growth in the private sector while insulin dominates SUS volumes; (3) Cardiovascular — the highest-volume chronic therapy area in Brazil with antihypertensives, statins, and anticoagulants; generic-dominant but branded premium opportunities exist in newer anticoagulants and SGLT-2 inhibitors; (4) Immunology and biologics — TNF inhibitors, IL-17 inhibitors, JAK inhibitors growing in private supplementary insurance; biosimilar adoption accelerating as ANVISA-approved biosimilars expand; (5) Infectious disease — Brazil has a globally recognised HIV/ARV programme fully funded by SUS; emerging opportunities in RSV, CMV, and antimicrobial resistance surveillance.

BioNixus HCP and KOL recruitment in Brazil combines five sourcing methods: (1) CRM de Médicos / Conselho Federal de Medicina registry validation to confirm CRM registration and specialty; (2) hospital network access through academic medical centres (Hospital das Clínicas USP, INCA, Hospital Albert Einstein, Hospital Sírio-Libanês) and regional public hospitals via CEP partner relationships; (3) specialty society lists and congress attendee networks across SBC (cardiology), SBOC (oncology), SBD (diabetes), SBI (infectious disease), and ABR (rheumatology); (4) digital professional panels for online quantitative surveys with credentialing checks; and (5) peer-referral snowball sampling for hard-to-reach specialties and KOL identification. All HCP panellists are screened against inclusion criteria, verified for active clinical practice, and compensated in line with INTERFARMA and CFM guidance.

BioNixus provides cross-regional intelligence for Brazilian and Latin American pharmaceutical companies entering GCC and MENA markets. Brazil and GCC share structural parallels — large generic medicine markets, centralised public procurement (SUS/NUPCO), and premium private hospital sectors — that make cross-regional strategy natural. From our regional offices, BioNixus delivers SFDA (Saudi Arabia), MOHAP (UAE), and MOH (Kuwait, Qatar, Oman) regulatory pathway intelligence; NUPCO tender and hospital formulary data; HCP surveys across all major therapy areas in Arabic and English; and comparative Brazil–GCC market benchmarking that informs portfolio sequencing and pricing strategy for companies launching in both regions.